下一代医疗事务：GenAI 的医疗响应和文献综述.pdf

1、2024 Databricks Inc.All rights reservedMathias Faux(Vertex Pharma)|Unmesh Kulkarni(Tredence)Mathias Faux(Vertex Pharma)|Unmesh Kulkarni(Tredence)June 13,2024June 13,20241POWERING THE POWERING THE NEXTNEXT-GEN GEN GLOBAL MEDICAL GLOBAL MEDICAL AFFAIRSAFFAIRS2024 Databricks Inc.All rights reserved2024

2、 Databricks Inc.All rights reserved2 2MATHIAS FAUXMATHIAS FAUXDirector of Analytics and Innovation Medical AffairsUnmesh KulkarniUnmesh KulkarniSenior Vice PresidentGenerative AIYOUR SPEAKERS TODAYYOUR SPEAKERS TODAY2024 Databricks Inc.All rights reserved2024 Databricks Inc.All rights reservedWHAT W

3、E ARE GOING TO COVERWHAT WE ARE GOING TO COVER331.Introduction of Vertex and Tredence2.Orientation of the role Global Medical Affairs plays3.The business problem4.Hi-level solution and architecture5.Learnings through the journey 2024 Databricks Inc.All rights reserved2024 Databricks Inc.All rights r

4、eservedCystic FibrosisSickle Cell DiseaseTransfusion dependent beta thalassemiaCystic FibrosisSickle Cell DiseaseTransfusion dependent beta thalassemia4Vertex Pharma at a glanceVertex Pharma at a glance4Current therapeutic areas servedCurrent therapeutic areas servedFuture therapeutic areas targeted

5、Future therapeutic areas targetedNonNon-opioid acute painopioid acute painAPOL1APOL1-Mediated Kidney DiseaseMediated Kidney DiseaseType 1 DiabetesMyotonic Dystrophy Type 1AlphaType 1 DiabetesMyotonic Dystrophy Type 1Alpha-1 Antitrypsin Deficiency1 Antitrypsin DeficiencyMathias2024 Databricks Inc.All

6、 rights reservedMEDICAL AFFAIRS MEDICAL AFFAIRS THE BRIDGE THE BRIDGE BETWEEN SCIENTIFIC EXCELLENCE BETWEEN SCIENTIFIC EXCELLENCE AND PATIENT VALUEAND PATIENT VALUE5Disseminate accurate,up-to-date medical and scientific information and lead educational healthcare initiatives Stakeholder Stakeholder